Moderna Inc (NASDAQ) (MRNA) Given $28.63 Consensus Price Target by Analysts

Moderna Inc (NASDAQ) (NYSE:MRNA) has received a consensus broker rating score of 1.19 (Strong Buy) from the eight brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a buy rating and six have assigned a strong buy rating to the company. Moderna Inc (NASDAQ)’s rating score has improved by 1.7% in the last three months as a result of various analysts’ ratings changes.

Brokers have set a 1 year consensus target price of $28.63 for the company and are anticipating that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also given Moderna Inc (NASDAQ) an industry rank of 92 out of 256 based on the ratings given to its competitors.

Separately, Chardan Capital reaffirmed a “buy” rating on shares of Moderna Inc (NASDAQ) in a research report on Sunday, April 7th.

MRNA traded down $1.58 during trading on Friday, reaching $21.88. 6,670 shares of the stock traded hands, compared to its average volume of 952,087. Moderna Inc has a 12 month low of $13.03 and a 12 month high of $29.79.

Moderna Inc (NASDAQ) Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Story: What are popular range trading strategies?

Get a free copy of the Zacks research report on Moderna Inc (NASDAQ) (MRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Moderna Inc (NASDAQ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna Inc (NASDAQ) and related companies with MarketBeat.com's FREE daily email newsletter.